DEF: T Stamp Inc. Seeks Stockholder Approval for Private Placement Warrants Issuance

T Stamp Inc. is holding a special meeting on February 7, 2025, to seek stockholder approval for the issuance of private placement warrants and related shares.

Summary

• T Stamp Inc. is holding a special meeting of stockholders on February 7, 2025, to vote on the ratification of the issuance of private placement warrants and the shares issuable upon exercise of those warrants.
• The warrants were issued as part of a securities purchase agreement with Armistice Capital Master Fund Ltd. on December 5, 2024.
• The company is seeking approval to comply with Nasdaq listing rules.
• The private placement warrants consist of Series A warrants for up to 5,555,548 shares and Series B warrants for up to 4,166,661 shares, both at an exercise price of $0.54 per share.
• The company raised approximately $3.0 million in gross proceeds from the related offering.
• If all private placement warrants are exercised for cash, the company could receive an additional $5,249,993 in gross proceeds.
• The primary use of the net proceeds will be for working capital, capital expenditures, and other general corporate purposes.
• The company must hold additional meetings every 90 days to seek approval if it is not obtained at the first meeting.

Sentiment

Score: 6

Explanation: The document is neutral in tone, focusing on the procedural aspects of seeking shareholder approval for a financial transaction. While the potential for additional capital is positive, the dilution risk and the need for repeated meetings if approval is not obtained temper the overall sentiment.

Positives

• The company has secured $3.0 million in gross proceeds through a registered direct offering and private placement.
• The potential exercise of private placement warrants could bring in an additional $5,249,993 in gross proceeds.
• The funds will be used for working capital, capital expenditures, and general corporate purposes.

Negatives

• Existing stockholders will experience dilution in their ownership if the private placement warrants are exercised.
• Failure to obtain stockholder approval will require the company to hold additional meetings every 90 days.
• If the private placement warrants cannot be exercised, the company will not receive the potential $5,249,993 in gross proceeds.

Risks

• The failure to obtain stockholder approval for the private placement warrants could impact the company's ability to raise additional capital.
• The exercise of the private placement warrants will dilute the ownership of existing stockholders.
• The sale of shares issued upon exercise of the warrants could negatively impact the market price of the company's stock.

Future Outlook

The company intends to use the net proceeds from the offering for working capital, capital expenditures, and other general corporate purposes. The company is also required to file a registration statement for the resale of shares issued upon exercise of the private placement warrants.

Management Comments

• Gareth Genner, Chief Executive Officer, encourages stockholders to review the proxy materials and vote as soon as possible.
• The Board recommends that stockholders vote FOR the ratification and approval of the issuance of the Private Placement Warrants.

Industry Context

This type of financing activity is common for companies seeking to raise capital for operations and growth. The need for shareholder approval for the issuance of warrants is a standard requirement under Nasdaq listing rules.

Comparison to Industry Standards

• The use of private placements and warrants is a common method for raising capital, particularly for smaller companies.
• The 7% placement agent fee is within the typical range for such transactions.
• The lock-up agreements for officers and directors are standard practice to ensure stability after a capital raise.
• The requirement to register the resale of shares issued upon exercise of warrants is a standard regulatory requirement.

Stakeholder Impact

• Shareholders will experience potential dilution if the private placement warrants are exercised.
• The company's ability to fund operations could be impacted if the private placement warrants are not approved.
• The company's share price could be affected by the sale of shares issued upon exercise of the warrants.

Next Steps

• Stockholders are to vote on the ratification of the private placement warrants at the special meeting on February 7, 2025.
• The company will file a registration statement for the resale of shares issued upon exercise of the private placement warrants.
• The company will hold additional meetings every 90 days to seek approval if it is not obtained at the first meeting.

Key Dates

Keywords

private placement warrants, stockholder approval, Armistice Capital, Nasdaq Listing Rule, share dilution, capital raise, special meeting, common stock